Taking stock of the drug industry, from the lab to the medicine chest

August 12, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Manuel Balce Ceneta/AP Opinion: The FDA should withdraw approval of more than 400 tainted medicines After learning about fraudulent work by a drug testing company in India, the FDA should have taken the drugs off the market. It didn't. By Suzanne Robotti Opinion: Some 'inconvenient' truths about pharmacy benefit managers PBMs are seen as middlemen that contribute little except for driving up prescription drug prices. Their true roles need to be clarified. By T. Joseph Mattingly II, David A. Hyman, and Ge Bai STAT+ | Three MDMA therapy papers retracted over data integrity concerns The journal Psychopharmacology retracted three papers about MDMA therapy, days after the FDA rejected Lykos' application for approval. By Meghana Keshavan

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser